[Immunologic characteristics of neonates with sepsis].
Explore the source record for details and available documents.
Bacterial Infections↗
Biomedical subjects
S A Samsygin
Publications and source records attributed to S A Samsygin.
[T- and B-populations of lymphocytes in congenital immune deficiencies].
Explore the source record for details and available documents.
Adolescent↗
[Globulin producing cells in cultures of blast-transformed lymphocytes in vitro].
Globulin-producing cells -- lymphocytes, transitional transformed forms, blasts and plasmocyte-like cells were revealed with the aid of Coon's method in the culture of the human peripheral blood following stimulation with staphylococcus filtrate and phytohemagglutinin. Analysis of dynamics of the appearance of these cells suggests that they originate from a special B-lymphocyte subpopulation -- the immunological memory cells. Some of the globulin-producing cells arose from precursors without any division, in others differentiation was combined with proliferation.
Adult↗
[The efficacy of specific plasma in the therapy of newborn infants with a Pseudomonas aeruginosa surgical infection].
141 newborn with purulent surgical infection were under observation. In 73 the inflammatory process was not induced by Pseudomonas aeruginosa in 68 the infection was caused by the blue pus bacillus. Bacteriological and immunological examination was conducted, including that with the use of enzyme immunoassay, to monitor the optical density of anti-pyocyanea antibodies during the course of the disease. It was found that the serum of a healthy newborn baby contains antibodies to Pseudomonas pyocyanea and did no differ from that of healthy older children in the level of anti-pyocyanea antibodies. The increase of the level of anti-pyocyanea antibodies in response to infection with Pseudomonas pyocyanea is twice less in newborns than older children with this infection. The use of specific plasma is much more effective than the administration of nonhyperimmune plasma. The efficacy of treatment with anti-pyocyanea plasma is determined by the level of anti-pyocyanea antibodies produced in the patient as a result of plasmatherapy rather than the volume of the dose given for the course.
Acute Disease↗